Skip to main content

Table 1 socio-demographic characteristics of patients who developed severe adverse effects in the Democratic Republic of Congo, over the 2003–2017 period

From: Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo

Parameters Category Mean ± SD
or Me (IQR)
N (%)
Age (years) 38.6 ± 15.5  
Sex
 Male   670 (70.9)
 Female   275 (29.1)
Patient’s health status
 Onchocerciasis   
 Confirmed   0 (0.0)
 Suspected   936 (99.1)
 Negative   9 (0.9)
Loiasis
 Confirmed   857 (90.7)
 Suspected   30 (3.2)
 Negative   58 (6.1)
Schistomiasis
 Confirmed   0 (0.0)
 Suspected   3 (0.3)
 Negative   942 (99.7)
Lymphatic filariasis
 Confirmed   0 (0.0)
 Suspected   3 (0.3)
 Negative   942 (99.7)
Information on the last treatment
 Ivermectin dosage (number of tablets per patient) 3.6 ± 0.6  
 Hemp consumption 24 h before ivermectin treatment   110 (11.6)
 Alcohol consumption 24 h before ivermectin treatment   206 (26.3)
 Microfilaraemia (mf/ml) upon admission 1200 (440–14,400)  
Onset of adverse effects (hours) 24 (8–96)  
Duration of hospitalisation (days) 7 (5–10)  
Status at discharge   
Recovery   890 (94.2)
Death   55 (5.8)
  1. SD = standard deviation, N = number, IQR = interquartile range